Procept BioRobotics Overview
Latest ROE for Procept BioRobotics: -32.27% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow-32.27%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Procept BioRobotics (PRCT) currently reports a ROE of -32.27%. That is below the Healthcare sector average of 22.01%. Use the charts on this page to explore Procept BioRobotics's ROE history and peer comparisons.
Procept BioRobotics's ROE of -32.27% is lower than the Healthcare sector average of 22.01%. That is roughly 246.6% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Procept BioRobotics's current -32.27% should be judged against Healthcare norms (sector average: 22.01%) and against PRCT's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of -32.27%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 22.01%. From there, open related valuation or income-statement pages for Procept BioRobotics, and consider following PRCT for alerts when major investors trade the stock.
Procept BioRobotics is classified in the Healthcare sector. On ROE, it currently shows -32.27% versus a sector average near 22.01%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing PRCT with unrelated industries.
